ADMA Biologics (ADMA) Stock Statistics & Valuation Metrics

ADMA Biologics has a market cap or net worth of $3.58B. The enterprise value is $3.53B.

ADMA Biologics has 238,159,180 shares outstanding. The number of shares has decreased by -2.65% in one year.

ADMA Biologics’s return on equity (ROE) is 0.31 and return on invested capital (ROIC) is 27.57%.

The current PE Ratio of ADMA Biologics is 29.6. ADMA Biologics’s PEG ratio is -1.09.

In the last 12 months, ADMA Biologics had revenue of 510.17M and earned 146.93M in profits. Earnings per share was 0.62.

In the last 12 months, operating cash flow was 50.40M and capital expenditures -22.57M, giving a free cash flow of 27.82M billion.

ADMA Biologics pays an annual dividend of ―, resulting in a dividend yield of ―

ADMA Biologics upcoming earnings date is May 13, 2026, TBA (Confirmed).

ADMA Biologics as a current ratio of 6.71, with Debt / Equity ratio of 16.74%

In the past 12 months, ADMA Biologics has paid 35.73M in taxes.

ADMA Biologics EV to EBITDA ratio is 21.93, with an EV/FCF ratio of 155.96.

ADMA Biologics has $87.63M in cash and marketable securities with $79.89M in debt, giving a net cash position of $7.75M billion.

Gross margin is 57.39%, with operating margin of 37.53%, and net profit margin of 28.80%.

The average price target for ADMA Biologics is $30.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy